Investigating the Neuronal and Network-Level Mechanisms Underlying Alzheimer’s Disease
Apr
20
2026
Apr
20
2026
Description
Dr. Andrew George is an assistant professor of Pharmacology and Toxicology at the Virginia Commonwealth University.
Alzheimer’s disease (AD) is a neurodegenerative condition that progressively destroys memory and cognition, exacting devastating personal and public health costs. Recent evidence indicates that soluble oligomeric Aβ42 (oAβ42) begins accumulating in the human brain one to two decades before clinical symptoms of AD emerge. Multiple studies suggest that elevated levels of soluble oAβ42, rather than insoluble Aβ plaques, drive the selective degeneration of vulnerable neurons and serve as the strongest predictors of cognitive decline in AD. Basal forebrain cholinergic neurons (BFCNs) are particularly vulnerable to functional modulation by oAβ42, and their dysfunction has been implicated in memory loss and cognitive impairment. In septo-hippocampal pathways, α7-containing nicotinic acetylcholine receptors mediate synaptic transmission and neuronal intrinsic excitability. While most α7 nicotinic acetylcholine receptors (nAChRs) are homomeric, α7β2-containing nAChRs are preferentially expressed on BFCNs. Using single-channel electrophysiology, we show that oAβ42 activates both α7- and α7β2- nAChR subtypes, with a preferential enhancement of α7β2-nAChR single-channel open dwell times. In parallel, current-clamp recordings from BFCNs in organotypic slice cultures prepared from male and female ChAT-EGFP mice demonstrate that chronic exposure to pathophysiologically relevant levels of oAβ42 enhances BFCN intrinsic excitability. These effects are associated with reduced afterhyperpolarization and altered rates of membrane depolarization and repolarization. Mechanistically, we find that oAβ42-α7β2 nAChR interactions enhance BFCN excitability through modulation of BK-, SK-, and KCNQ/Kv7 (M-type) potassium channels. Together, these findings identify α7β2-nAChRs and downstream potassium channel targets as potential therapeutic targets for preventing BFCN dysfunction and cognitive decline in AD.
Hosted by Dr. Harold Zakon
To subscribe to our Seminars Series mailing list, please visit https://utlists.utexas.edu/sympa/info/neu-seminars and click on "Subscribe" in the left-hand column.
Please contact Neuro.Seminar.Series@austin.utexas.edu with any questions.
Other Events in This Series
Sep
21
2026
Christina Alberini - Title TBA
2026-27 Neuroscience Seminar Series
3:00 pm – 4:00 pm • In Person
Speaker(s): Christina Alberini - New York University
Sep
28
2026
Julie Kauer - Title TBA
2026-27 Neuroscience Seminar Series
3:00 pm – 4:00 pm • In Person
Speaker(s): Julie Kauer - Stanford University
Nov
2
2026
Cengiz Pehlevan - Title TBA
2026-27 Neuroscience Seminar Series
3:00 pm – 4:00 pm • In Person
Speaker(s): Cengiz Pehlevan - Harvard University
Nov
9
2026
Denise Ferkey - Title TBA
2026-27 Neuroscience Seminar Series
3:00 pm – 4:00 pm • In Person
Speaker(s): Denise Ferkey - University of Buffalo
Jan
11
2027
D. Kacy Cullen - Title TBA
2026-27 Neuroscience Seminar Series
3:00 pm – 4:00 pm • In Person
Speaker(s): D. Kacy Cullen - University of Pennsylvania
Jan
25
2027
Loren Frank - Title TBA
2026-27 Neuroscience Seminar Series
3:00 pm – 4:00 pm • In Person
Speaker(s): Loren Frank - UCSF
Feb
8
2027
David Perkel - Title TBA
2026-27 Neuroscience Seminar Series
3:00 pm – 4:00 pm • In Person
Speaker(s): David J. Perkel - University of Washington
Mar
1
2027
Morgan Barense - Title TBA
2026-27 Neuroscience Seminar Series
3:00 pm – 4:00 pm • In Person
Speaker(s): Morgan Barense - University of Toronto
Mar
8
2027
Robert Desimone - Title TBA
2026-27 Neuroscience Seminar Series
3:00 pm – 4:00 pm • In Person
Speaker(s): Robert Desimone - Massachusetts Institute of Technology
Apr
5
2027
Ryohei Yasuda - Title TBA
2026-27 Neuroscience Seminar Series
3:00 pm – 4:00 pm • In Person
Speaker(s): Ryohei Yasuda - Max Planck Florida Institute